Monopar and NorthStar Announce Filing of Provisional Patent Protecting Development and Use of Radio-Immuno-Therapeutics (RITs) Targeting Severe COVID-19 Through uPAR
30 juin 2020 08h25 HE
|
Monopar Therapeutics Inc.
CHICAGO and BELOIT, Wis., June 30, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Chicago, IL) and NorthStar Medical Radioisotopes, LLC (Beloit, WI) announced today that a...
Monopar and NorthStar Join Forces to Develop Radio-Immuno-Therapeutics (RITs) Targeting Severe COVID-19
16 juin 2020 08h25 HE
|
Monopar Therapeutics Inc.
CHICAGO and BELOIT, Wis., June 16, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Chicago, IL) and NorthStar Medical Radioisotopes, LLC (Beloit, WI) announced today a 50/50...
Monopar Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Business Updates
27 mars 2020 09h15 HE
|
Monopar Therapeutics Inc.
Initial public offering on Nasdaq Capital Market in December 2019 Orphan Drug Designation from the European Commission for camsirubicin for the treatment of soft tissue sarcoma CHICAGO, March 27,...
Monopar Therapeutics Inc. Announces Closing of Initial Public Offering of Common Stock
23 déc. 2019 12h30 HE
|
Monopar Therapeutics Inc.
CHICAGO, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. today announced the closing of its initial public offering of 1,277,778 shares of common stock, including the underwriters’...